Xinhua Finance, Nanjing, August 18 (Reporter: Zhu Cheng) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively.

The results announcement shows that in the first half of this year, Sino Biopharm's R&D expenses reached RMB 3.19 billion, an increase of RMB 610 million from the same period last year. The ratio of R&D expenses to revenue reached 18.1%, also a 1.9 percentage point increase from the same period last year. Of this, R&D expenses for innovative drugs and biosimilars accounted for 78%. The resulting innovative product revenue reached RMB 7.8 billion in the first half of 2025, representing a year-on-year increase of 27.2%.

As of the end of the reporting period, Sino Biopharm's cash reserves reached RMB 30.5 billion. The company proposes to distribute a dividend of RMB 820 million for the first half of 2025, an increase of over 60% compared to the same period last year.

It is reported that in the past two years, Sino Biopharm has successively received approval for 11 innovative products. The company projects that for the full year of 2025, the growth rate of innovative product revenue will exceed 25%, contributing over RMB 3 billion in incremental revenue. Products such as third-generation G-CSF, PD-L1, KRAS, and Pertuzumab will be the core drivers of performance this year.

Sino Biopharm expects that another 19 innovative products will be approved between 2025 and 2027. More than half of these are blockbuster products with potential peak sales exceeding RMB 2 billion.

Ms. Theresa Tse, Chairwoman of the Board of Sino Biopharm, stated, "Since the middle of last year, the company's performance has achieved strong double-digit growth for three consecutive reporting periods, fully demonstrating that our R&D pipeline has entered a period of intensive harvest".

Editor: Wang Yuanyuan